Sajeev Cherian

1.4k total citations
16 papers, 1.1k citations indexed

About

Sajeev Cherian is a scholar working on Molecular Biology, Oncology and Pathology and Forensic Medicine. According to data from OpenAlex, Sajeev Cherian has authored 16 papers receiving a total of 1.1k indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Molecular Biology, 5 papers in Oncology and 4 papers in Pathology and Forensic Medicine. Recurrent topics in Sajeev Cherian's work include Protein Kinase Regulation and GTPase Signaling (5 papers), Genetic factors in colorectal cancer (4 papers) and Colorectal Cancer Screening and Detection (4 papers). Sajeev Cherian is often cited by papers focused on Protein Kinase Regulation and GTPase Signaling (5 papers), Genetic factors in colorectal cancer (4 papers) and Colorectal Cancer Screening and Detection (4 papers). Sajeev Cherian collaborates with scholars based in United States and United Kingdom. Sajeev Cherian's co-authors include C. Richard Boland, John M. Carethers, Minoru Koi, D P Chauhan, Asad Umar, Thomas A. Kunkel, R C Haggitt, David A. Crispin, Peter S. Rabinovitch and C.E. Rubin and has published in prestigious journals such as Blood, Gastroenterology and Hepatology.

In The Last Decade

Sajeev Cherian

15 papers receiving 1.1k citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Sajeev Cherian United States 11 638 593 470 351 114 16 1.1k
Masayuki Enomoto Japan 14 437 0.7× 364 0.6× 552 1.2× 222 0.6× 122 1.1× 33 1.2k
Takashi Kobunai Japan 23 621 1.0× 327 0.6× 727 1.5× 262 0.7× 90 0.8× 60 1.4k
Sandra Mongera Netherlands 17 694 1.1× 341 0.6× 377 0.8× 457 1.3× 86 0.8× 25 1.1k
Diane E. Brattain United States 16 731 1.1× 171 0.3× 492 1.0× 229 0.7× 106 0.9× 19 1.1k
Rachel Gredler United States 21 805 1.3× 770 1.3× 474 1.0× 292 0.8× 40 0.4× 24 1.3k
Do-Sun Byun United States 11 1.3k 2.0× 189 0.3× 614 1.3× 229 0.7× 110 1.0× 11 1.7k
Ellen P.S. Man Hong Kong 18 967 1.5× 275 0.5× 407 0.9× 277 0.8× 96 0.8× 24 1.3k
I Bae United States 7 1.1k 1.8× 138 0.2× 1.1k 2.2× 306 0.9× 120 1.1× 8 1.6k
Melinda Huang United States 6 464 0.7× 195 0.3× 500 1.1× 122 0.3× 57 0.5× 7 801
Sébastien Tardy Switzerland 13 929 1.5× 134 0.2× 730 1.6× 161 0.5× 143 1.3× 24 1.3k

Countries citing papers authored by Sajeev Cherian

Since Specialization
Citations

This map shows the geographic impact of Sajeev Cherian's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Sajeev Cherian with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Sajeev Cherian more than expected).

Fields of papers citing papers by Sajeev Cherian

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Sajeev Cherian. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Sajeev Cherian. The network helps show where Sajeev Cherian may publish in the future.

Co-authorship network of co-authors of Sajeev Cherian

This figure shows the co-authorship network connecting the top 25 collaborators of Sajeev Cherian. A scholar is included among the top collaborators of Sajeev Cherian based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Sajeev Cherian. Sajeev Cherian is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

16 of 16 papers shown
1.
Cherian, Sajeev, et al.. (2024). A Case Series on Post Essential Thrombocytosis Myelofibrosis Conversion to Chronic Myeloid Leukemia. Blood. 144(Supplement 1). 6613–6613.
2.
Cherian, Sajeev. (2009). IT Enabled Innovation: A Theoretical and Empirical Investigation of the Role of Information Technology and Outsourcing in Business Innovation. Journal of the Association for Information Systems. 1 indexed citations
3.
Cherian, Sajeev & Judith S. Olson. (2007). Extending a theory of remote scientific collaboration to corporate contexts. 2321–2326. 1 indexed citations
4.
Han, Edward K., Laura Gehrke, Sajid Khan Tahir, et al.. (2000). Modulation of drug resistance by α-tubulin in paclitaxel-resistant human lung cancer cell lines. European Journal of Cancer. 36(12). 1565–1571. 43 indexed citations
5.
Tahir, Sajid Khan, Wen‐Zhen Gu, Juan H. Leal, et al.. (2000). Inhibition of farnesyltransferase with A-176120, a novel and potent farnesyl pyrophosphate analogue. European Journal of Cancer. 36(9). 1161–1170. 10 indexed citations
6.
Han, Edward K., et al.. (2000). Modulation of paclitaxel resistance by annexin IV in human cancer cell lines. British Journal of Cancer. 83(1). 83–88. 88 indexed citations
7.
Wang, Shen, Stephen A. Fakhoury, Kenneth J. Henry, et al.. (1999). Potent inhibitors of protein farnesyltransferase: Heteroarenes as cysteine replacements. Bioorganic & Medicinal Chemistry Letters. 9(5). 703–708. 7 indexed citations
8.
Gu, Wen‐Zhen, Sajeev Cherian, Stephen J. O’Connor, et al.. (1999). Effect of novel CAAX peptidomimetic farnesyltransferase inhibitor on angiogenesis in vitro and in vivo. European Journal of Cancer. 35(9). 1394–1401. 37 indexed citations
9.
Augeri, David J., Douglas Kalvin, Daniel A. Dickman, et al.. (1999). Potent and orally bioavailable noncysteine-containing inhibitors of protein farnesyltransferase. Bioorganic & Medicinal Chemistry Letters. 9(8). 1069–1074. 28 indexed citations
10.
Henry, Kenneth J., James T. Wasicak, Andrew S. Tasker, et al.. (1999). Discovery of a Series of Cyclohexylethylamine-Containing Protein Farnesyltransferase Inhibitors Exhibiting Potent Cellular Activity. Journal of Medicinal Chemistry. 42(23). 4844–4852. 17 indexed citations
11.
Macdonald, Graeme A., et al.. (1998). Microsatellite instability and loss of heterozygosity at DNA mismatch repair gene loci occurs during hepatic carcinogenesis. Hepatology. 28(1). 90–97. 74 indexed citations
12.
Augeri, David J., Stephen J. O’Connor, Bruce G. Szczepankiewicz, et al.. (1998). Potent and Selective Non-Cysteine-Containing Inhibitors of Protein Farnesyltransferase. Journal of Medicinal Chemistry. 41(22). 4288–4300. 38 indexed citations
13.
Brentnall, Teresa A., David A. Crispin, Mary P. Bronner, et al.. (1996). Microsatellite instability in nonneoplastic mucosa from patients with chronic ulcerative colitis.. PubMed. 56(6). 1237–40. 228 indexed citations
14.
Luce, Michael C., Giancarlo Marra, Dharam P. Chauhan, et al.. (1995). In vitro transcription/translation assay for the screening of hMLH1 and hMSH2 mutations in familial colon cancer. Gastroenterology. 109(4). 1368–1374. 58 indexed citations
15.
Koi, Minoru, Asad Umar, D P Chauhan, et al.. (1994). Human chromosome 3 corrects mismatch repair deficiency and microsatellite instability and reduces N-methyl-N'-nitro-N-nitrosoguanidine tolerance in colon tumor cells with homozygous hMLH1 mutation.. PubMed. 54(16). 4308–12. 441 indexed citations
16.
Fox, Floyd E., et al.. (1993). Evidence That TGF-β Can Inhibit Human T-Lymphocyte Proliferation through Paracrine and Autocrine Mechanisms. Cellular Immunology. 150(1). 45–58. 51 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026